A new Canadian study clarifies recent research indicating that the drugs increase the risk of atypical fractures in the femur and the bone just below the hip joint.
This result is particularly troublesome because the drug is designed to reduce the risk of common fractures associated with osteoporosis. The risk of these atypical fractures merely adds to the pre-existing concerns regarding the link between bisphosphonates and osteonecrosis of the jaw (ONJ). Osteonecrosis is a debilitating condition of the jawbone that causes infection and deterioration of the jawbone.
If you or someone you love has suffered severe side effects from the use of bisphosphonates like Fosamax, including atypical fractures or the development of ONJ, you may be entitled to compensation. The Fosamax lawyers at Montlick and Associates, Attorneys at Law, have been fielding calls from clients throughout the U.S. regarding serious Fosamax injuries.
The new Canadian study involved women with osteoporosis being treated with bisphosphonates like Fosamax and found that the long-term use of the drugs was linked to a 2.7 times greater likelihood of suffering an atypical bone fracture. The study further found that atypical fractures occurred in 0.13% of women who had taken bisphosphonates for five years or more. The researchers have recommended a break from Fosamax treatment to doctors and patients once a patient has been treated with the drug for five years.
Montlick represents clients injured by dangerous medical devices and defective drugs. If you have suffered serious side effects related to your use of Fosamax, such as osteonecrosis of the jaw, contact Montlick and Associates to discuss your legal rights.
